Gland Pharma receives USFDA EIR for Dundigal Facility
Advertisement
Hyderabad: Through a recent BSE filing, Gland Pharma has informed that the Company has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration (US FDA) indicating the closure of the inspection at its Dundigal Facility in Hyderabad.
USFDA had inspected the facility between 03rd July, 2023 to 14th July, 2023 and issued one 483 Observation.
Read also: Gland Pharma to infuse Rs 400 crore to expand Genome Valley facility
Gland Pharma, a generic injectable-focused pharmaceutical company, was established in 1978 in Hyderabad. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.